anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
OBJECTIVE: To explore early effectiveness of unilateral biportal endoscopy (UBE) technique in the treatment of migrated lumbar intervertebral disc herniation.
METHODS: A retrospective analysis was conducted on 87 patients with migrated lumbar intervertebral disc herniation, who were treated with UBE technique between May 2021 and December 2022 and met the selection criteria. There were 55 males and 32 females, with an average age of 48.8 years (range, 29-74 years). The disease duration ranged from 2 to 23 months, with an average of 9.1 months. The surgical segments included 17 cases of L 3, 4, 32 cases of L 4, 5, and 38 cases of L 5, S 1. According to Lee's classification criteria, there were 12 cases of type 1, 17 cases of type 2, 37 cases of type 3, and 21 cases of type 4. The operation time, length of hospital stay, and complications were recorded. The visual analogue scale (VAS) score was used to assess the degree of low back and leg pain before operaion and at 3 days, 3 months, 6 months, and 12 months after operation. The Oswestry disability index (ODI) was used to evaluate the lumbar spine function. At last follow-up, the modified MacNab criteria was used to evaluate the effectiveness. According to the preoperative migrated intervertebral disc classification, the patients were allocated into groups Ⅰ to Ⅳ. The differences in VAS score and ODI were compared.
RESULTS: All 87 patients successfully completed the operations. There was no nerve root injury, dural sac injury, or dural tear during operation. The operation time was (58.6±14.6) minutes and the length of hospital stay was (4.0±0.8) days. All incisions healed by first intention after operation. No symptomatic epidural hematoma occurred. All patients were followed up for 12 months. There were significant differences in VAS scores and ODI at each time point after operation when compared with those before operation ( P<0.05). There were significant differences in VAS score at 3 days after operation when compared with that at 3, 6, and 12 months after operation ( P<0.05). For ODI, except that there was no significant difference between 6 and 12 months after operation ( P>0.05), there were significant differences between other time points after operation ( P<0.05). At last follow-up, the effectiveness was rated as excellent in 66 cases, good in 13 cases, and fair in 8 cases according to the modified MacNab criteria, and the excellent and good rate was 90.8%. There was no intervertebral disc herniation recurred during follow-up period. There was no significant difference in VAS score and ODI among groups Ⅰ -Ⅳ before operation and at each time point after operation ( P>0.05).
CONCLUSION: The UBE technique is safe and effective in the treatment of migrated lumbar intervertebral disc herniation, with a low complication rate and satisfactory early effectiveness.
BACKGROUND: There is limited evidence as to whether the immune protein profile is associated with a particular symptomatology pattern across the psychosis continuum.
METHODS: We estimated two bifactor models of general and specific dimensions of psychotic experiences in unaffected siblings of patients (n = 52) and community controls (n = 200), and of psychotic symptoms in first-episode psychosis (FEP) patients (n = 110). We evaluated associations between these transdiagnostic dimensions and trait (TNF-α, IFN-γ), state (IL-6, IL-1β), and regulatory (TGF-β, IL-10, IL-4) cytokines. We explored whether schizophrenia genetic liability (schizophrenia polygenic risk score; SZ-PRS) modified the associations.
RESULTS: High levels of trait marker IFN-γ were associated with the severity of general psychosis dimension in the unaffected siblings and community controls, expanding to the depressive dimension in siblings and to the manic dimension in FEP. High TNF-α levels were associated with more positive psychotic experiences in unaffected siblings and manic symptoms in FEP. Low levels of state markers IL-6 and IL-1β were observed in unaffected siblings presenting more depressive experiences. Still, high levels of IL-6 and IL-1β were associated with the severity of the depressive and negative symptom dimensions at FEP. The severity of transdiagnostic dimension scores across the three groups was associated with lower regulatory cytokines. Exploratory analysis suggested that a high SZ-PRS contributed mostly to associations with psychotic dimensions.
CONCLUSIONS: IFN-γ mapped onto the multidimensional expression of psychosis, reinforcing the trait concept. State markers IL-6 and IL-1β may fluctuate along the spectrum. Dysfunction in the regulatory arm may disinhibit the inflammatory system. Associations with psychotic dimensions may be more prone to SZ-PRS susceptibility.
BACKGROUND: Masson's tumor, commonly referred to as intravascular papillary endothelial hyperplasia (IPEH), is an uncommon growth of endothelial cells within a vessel wall that is frequently assumed to indicate an abnormal resolution of thrombosis. IPEH is most typically found in the extremities however it is rare for IPEH to appear as a neck tumor. The issue with IPEH is that it could clinically, radiologically, and pathologically imitate some malignant neoplasms such as angiosarcomas creating a diagnostic challenge.
CASE REPORT: We describe a 21-year-old male patient who presented with right anterolateral neck swelling for 12 months. Ultrasound revealed a 9.0 × 8.0 cm well-defined echogenic hyper-vascular lesion. The contrast computed tomography (CT) scan of the neck revealed an oval, well-defined subcutaneous mass, measuring 9 × 4.5 cm, situated over and separable from the right sternocleidomastoid muscle with no significant enhancement in the post-contract study. T1-weighted and T2-weighted MRI revealed a 10 × 9 × 7 cm well-defined subcutaneous lobulated lesion superficial to the sternocleidomastoid expanding upward to the Rt. side of the cheek and below to the suprasternal region, eliciting an intermediate signal in T1 and a heterogenous bright signal (mostly fluid) in T2 with low signal foci within the mass. The decision had been reached to entirely excise the lesion surgically with safety margins for histological evaluation. Histological examination indicated thrombosed variable-sized ectatic vascular spaces with papillary formations related to the thrombus, covered with a single layer of flat endothelium, and no features suggestive of malignancy. There was no recurrence at 18 months follow-up post-surgery.
CONCLUSION: Masson's tumor is a benign intravascular disease with an unclear origin and no confirmed inheritance pattern. Presentation of Masson's tumor as a neck mass is incredibly uncommon. Masson's tumor lacks a distinct or distinguishing clinical and radiological appearance. Histopathologic examination is the sole definitive way for diagnosing the disease and the only tool for distinguishing it from angiosarcoma. Surgical excision is the best treatment for IPEH. Recurrence is extremely rare.
PURPOSE:To obtain a dermal cosmetic having excellent dermal senescence- preventing effect, beautiful skin effect, safety and stability with time, containing a sulfhydryloxydase (SHase) and water-soluble polyhydric alcohol. CONSTITUTION:The aimed dermal cosmetic contains SHase as an enzyme polym erizing protein or peptide by bonding SH group of protein or peptide and forming S-S bond and a water-soluble polyhydric alcohol, e.g. ethylene glycol, propylene glycol, glycerin, glucose or maltose. Mixing amount of SHase is preferably 0.00001-0.1wt.% and a water-soluble polyhydric alcohol is preferably 50-5000wt. times of SHase. SHase acts as a catalyst of mutual bonding free SH groups existing in the most outer layer of skin and perform tylosis and keratinization of corneum cell membrane, densification of the surface structure, improvement of dried skin, enhancement of water-retentive mechanism and improvement of wet-preservation of skin.
The invention relates to a medicine biological particle preparation, a preparation method and application thereof, belonging to the technical field of medicines. Solves the technical problem of poor infusion treatment effect of bladder cancer. The drug carrier of the drug biological particle preparation is submicron drug-carrying cell microvesicles which are generated by the extracellular membrane of the mouse bladder cancer cell MB49, the shape is spherical, and the particle size is about 400nm; the drug carrier is loaded with a chemotherapeutic drug. The peak value of the ultraviolet-visible absorption spectrum of the medicine biological particle preparation is consistent with the peak value of the absorption of the chemotherapeutic medicine pirarubicin. The drug carrier for carrying the drug is a cell microvesicle secreted by bladder cancer cells, so that the drug carrier has better killing property on bladder cancer cells than free drugs and shows specific killing property. The biological particle preparation of the medicine is used for bladder perfusion treatment of bladder in-situ transplantation tumor model mice, and experimental results show that the biological particle preparation has more remarkable effect of inhibiting bladder cancer compared with single use of pirarubicin perfusion.
Colorectal cancer (CRC) is the second most commonly diagnosed cancer and the third highest cause of mortality in Vietnamese and Asian Americans. CRC incidence is rising rapidly in Vietnamese Americans, but they have among the lowest rates of CRC screening (14%) and are more likely to be diagnosed with advanced stage disease, which is highly preventable. Over 85% of Vietnamese Americans in our region (PA, NJ, and NYC) are foreign-born with limited English proficiency, have low SES, and live in economically disadvantaged neighborhoods. Many lack knowledge about CRC risks and screening benefits and have limited access to culturally appropriate preventive care. Thus, a multilevel intervention is needed to address the multiple barriers to and determinants of CRC screening in this community. Vietnamese community organizations (VCOs) serve dynamic social functions and represent an important resource for addressing this critical health disparity priority by promoting CRC screening. This project builds on established partnerships and successful work of Center for Asian Health, Temple University with Vietnamese CBOs that address their overwhelming health disparities. CBPR principles will be applied to engage 20 VCOs in all phases of planning, implementing, evaluating, and disseminating a culturally appropriate, theory- and evidence-based multilevel CRC intervention. The proposed intervention will be guided by Social Ecological Model, which addresses sociocultural, behavioral and environmental determinants and intervention strategies at the individual, interpersonal, and community organizational levels. CDC's Clinical Preventive Services Guidelines for adults 50+ (CPS) recommend that cancer screenings and other preventive services should be promoted. The standard CPS will be provided to both intervention and control groups, and intervention group will receive CPS + multilevel CRC intervention. Specific Aim 1 is to test the hypothesis that CPS + multilevel CRC intervention will yield higher CRC screening rates compared to CPS control at 12-month follow up; Aim 2 is to examine whether CPS + multilevel CRC intervention (which includes CHW-led group education, automated and interactive text messaging and phone-based peer support) is more effective in changing screening determinants (e.g. KAB, self-efficacy, risk factors, lifestyles, social support, social norms, access barriers) than CPS control condition; and Aim 3 is to assess costs and cost-effectiveness of CPS + multilevel CRC intervention compared to CPS control condition in relation to CRC screening rates in order to inform future dissemination efforts. In sum, this project represents the first large-scale community-based randomized controlled trial of a multilevel, culturally-appropriate CBPR intervention to increase CRC screening among underserved Vietnamese. If effective, this innovative multilevel CRC intervention can be used as a model program that has potential generalizability and sustainability in Asian American and other underserved ethnic communities to impact preventive behaviors at the population level.
The present invention pertains to the field of medicine and more precisely relates to a method for diagnosing the action of medical preparations as well as medicating, psycho-corrective, mechanical and physiotherapeutic actions applied on the organism of a patient. This invention may be used in the field of pharmacy as well as in the practice in therapy institutes. After a preliminary study, the method of the present invention comprises selecting a research group and monitoring a group including patients of the same sex and approximately the same age. The patients are applied the therapy to be studied and a monitoring is carried out before drawing the conclusions about efficiency according to the treatment of the disease or the recovery and/or the prevention of a pathological symptom occurrence. The groups of subjects are divided by a number that ensures statistical certainty, with a period similar in each group starting from a disease relapse (aggravation) to the beginning of the patient's participation to the clinical experiment, and with an identical location of the pathological process. This method is characterised by an identical homeostatic condition especially concerning lipids. The therapeutic action is monitored for a time period which is calculated individually according to the selected groups. The therapeutic action efficiency is determined from the duration necessary for treating or curing the disease and/or preventing the occurrence of a pathological symptom and its effect on the homeostasis. The efficiency of the therapeutic action is also determined from its effects on the homeostasis in the case, for example, when the efficiency of said action depends on the homeostasis characteristics. The index discrepancies relative to average statistical values are estimated for the corresponding groups both when increasing or decreasing in the case of a given disease.
PURPOSE:To obtain an intravascular embolic agent, containing an arterialization inhibitor and an intravascular embolic substance and capable of enhancing carcinostatic effects of embolic therapy. CONSTITUTION:An intravascular embolic agent containing 0.01-95wt.% arterialization inhibitor, e.g. 6-0-(N-chloroacetylcarbamoyl)fumagillol and an intravascular embolic substance as active ingredients. The intravascular embolic substance is oils, metals, insoluble salts of the metals, ceramics, waxes, active carbon, polypeptides, polysacharides, polyfatty acid esters, polyamino acids, polyaldehydes, polyvinylic polymers, maleic anhydride-based polymers, etc. The aforementioned intravascular embolic agent contains particles having 10-1000mum particle diameter and can intravascularly be administered in a state of an oil solution, an emulsion or a suspension. Thereby, the dose of conventional arterialization inhibitors can be reduced to relieve side effects. The objective embolic agent is capable of exhibiting more powerful and sustained carcinostatic effects by its use with an anticancer agent in combination and useful as a chemical embolic agent against malignant tumors.
FIELD: organic chemistry. SUBSTANCE: product - derivatives of benzimidazole of the general formula 1 and 2 indicated in description where R 1  is not obligatory substituted alkyl group; R 2  and R 3  are independently each of other represent the group which is able to form anion, or the group which can be converted to the such group; ring A - benzene ring which does not obligatory contain other substituents apart from the group R 2 ; X - direct bond of phenylene group and phenyl group or linkage through the spatial group chain atoms of which does not exceed 2, or their salts. Reagent 1: compound of the general formula 2. Reaction conditions: intramolecular cyclodehydration following by conversion of product prepared to the compound of formula 1 by azidation, hydrolysis, reduction, halogenation, nucleophilic reaction, cyaniding and/or esterification or compound of the formula 1 is converted to its salt. Synthesized compounds are used as pharmaceutical preparations. EFFECT: improved method of synthesis. 1 tbl
Borderline elevations of one or more liver tests may occur in up to 15% of patients taking NSAIDs including indomethacin. These laboratory abnormalities may progress, may remain unchanged, or may be transient with continuing therapy. Notable elevations of ALT or AST (approximately three or more times the upper limit of normal) have been reported in approximately 1% of patients in clinical trials with NSAIDs. In addition, rare cases of severe hepatic reactions, including jaundice and fatal fulminant hepatitis, liver necrosis and hepatic failure, some of them with fatal outcomes have been reported.

A patient with symptoms and/or signs suggesting liver dysfunction, or in whom an abnormal liver test has occurred, should be evaluated for evidence of the development of a more severe hepatic reaction while on therapy with indomethacin. If clinical signs and symptoms consistent with liver disease develop, or if systemic manifestations occur (e.g., eosinophilia, rash, etc.), indomethacin should be discontinued.
Subjects participate in two study periods: During the first period (treatment A), they receive a single oral dose of rosuvastatin on Day 1. During the second period (treatment B), they receive a single oral loading dose of macitentan on Day 5 and oral doses of macitentan from Day 6 to Day 16 (i.e., 11 doses). Subjects receive a single oral dose of 10 mg rosuvastatin concomitantly with macitentan in the morning of Day 10.
Participants will use programmable weight machines along with free weights to target primary muscle groups. In addition, they will complete mini-squats, mini-lunges, and lunge walks. Participants will complete two sets of 6-8 reps. Training stimulus will be increased using the 7RM method - when 2 sets of 6-8 reps are completed with proper form and without discomfort. Investigators will record the number of sets completed and the load lifted for each exercise for each participant at every class.
The sample of the study will consist of patients who received chemotherapy treatment with the diagnosis of Stage IV non-small cell lung cancer in the outpatient chemotherapy service of a training and research hospital and met the inclusion criteria. Data in the study will be collected using the Patient Information Form, Eastern Cooperative Oncology Group (ECOG) Performance Scale, Cancer Dyspnea Scale, Leicester Cough Questionnaire and Cancer Fatigue Scale. In order to test the applicability and comprehensibility of the forms to be used before the study, a preliminary application will be made with 5 patients. This study is planned to prepare a video describing the application for patients to use while performing the Active Cycle of Breathing Techniques application. On the 1st day of the study, a 10-minute face-to-face training will be given to the intervention (experimental) group by the researcher using the video about the Active Cycle of Breathing Techniques. In the research, the intervention (experimental) group will be asked to follow the video to be prepared and apply the Active Cycle of Breathing Techniques twice a day for 28 days. The intervention (experimental) group will be monitored by telephone call once a week and 3 times using the Patient Follow-up Form (days 7, 14 and 21). On the other hand, only the pre-test and post-test will be applied to the control group.
Using a disposable face mask was inhale for ten minutes 0.25 ml of essential oil of eucalyptus measured through adjustable Pipettor 100/1000μl. Inhalation of the substance occurred immediately after the 20 minute rest period in the session Essential Oil of Eucalyptus.
An authentication system for allowing access to a user account server has at least one access device and at least one verification server. The at least one access device is capable of operatively connecting to the user account server and comprises a touch screen for allowing entry of session signatures. The at least one verification server is capable of comparing session signatures to reference signatures. A user reference signature is stored on the at least one verification server. The at least one access device allows entry of a user session signature and transmission of the user session signature to the at least one verification server. The at least one verification server allows the at least one user to connect to the user account server based on a comparison of the user session signature with the user reference signature.
PURPOSE: A Callophyllis japonica extract is provided to have an antioxidation property, to suppress the secretion of immunoglobulin E (IgE) and cytokines and the increase of inflammation by eosinophils, thereby being used as pharmaceutical products or food compositions for preventing or treating asthma. CONSTITUTION: A pharmaceutical composition for preventing or treating asthma contains a Callophyllis japonica extract as an active ingredient. The extract is a polar solvent extract. The polar solvent includes water, alcohol, or a mixture thereof. Alcohol is methanol or ethanol. A food composition for preventing or treating asthma contains the extract as an active ingredient. The food composition additionally contains one or more additives selected among organic acid, phosphate, an antioxidant, lactose, casein, dextrin, glucose, sugar, and sorbitol.
Isoniazid acts against actively growing tubercle bacilli.

Within one to two hours after oral administration, isoniazid produces peak blood levels which decline to 50 percent or less within six hours. It diffuses readily into all body fluids (cerebrospinal, pleural, and ascitic), tissues, organs, and excreta (saliva, sputum, and feces). The drug also passes through the placental barrier and into milk in concentrations comparable to those in the plasma. From 50 to 70 percent of a dose of isoniazid is excreted in the urine in 24 hours.

Isoniazid is metabolized primarily by acetylation and dehydrazination. The rate of acetylation is genetically determined. Approximately 50 percent of Blacks and Caucasians are slow acetylators and the rest are rapid acetylators; the majority of Eskimos and Orientals are rapid acetylators.

The rate of acetylation does not significantly alter the effectiveness of isoniazid therapy when dosage is administered daily. However, slow acetylation may lead to higher blood levels of the drug and thus an increase in toxic reactions.

Pyridoxine (B 6) deficiency is sometimes observed in adults with high doses of isoniazid and is considered probably due to its competition with pyridoxal phosphate for the enzyme apotryptophanase.
Receive the relational agent and the AliveCor Kardia for use for 120 days. Participants are directed to use these interventions daily.
Cognitive decline after stroke is a common sequela and is highly associated with functional disability. Empirical evidence shows that exercise combined cognitive training may induce neuroplastic changes that modulate cognitive function. However, evidence about the effects of combined exercise-cognitive trainings on physiological biomarkers, cognitive and physical functions in stroke patients with cognitive decline is still less. The present study aim to investigate the effects of sequential combination of exercise-cognitive trainings on cognitive, physical, and daily function. In addition, the physiological mechanism of the combination training on cognitive function by several biomarkers including the brain-derived neurotrophic factor (BDNF), antioxidative marker, HbA1c, and plasma lipid level will be investigated. This study is a single-blind randomized controlled trial. Participants will be randomly assigned to SEQ group in which sequentially perform physical exercise and cognitive training or to CI group of control intervention.